Prelude Therapeutics 경영진
경영진 기준 점검 4/4
Prelude Therapeutics CEO는 Kris Vaddi, Feb2016 에 임명되었습니다 의 임기는 10.25 년입니다. 총 연간 보상은 $1.35M, 45.7% 급여 및 54.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $13.31M 가치에 해당하는 회사 주식의 3.1% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.4 년과 6 년입니다.
핵심 정보
Kris Vaddi
최고경영자
US$1.3m
총 보수
| CEO 급여 비율 | 45.66% |
| CEO 재임 기간 | 10.3yrs |
| CEO 지분 보유율 | 3.1% |
| 경영진 평균 재임 기간 | 4.4yrs |
| 이사회 평균 재임 기간 | 6yrs |
최근 경영진 업데이트
Recent updates
분석 기사 • May 16
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...
새로운 내러티브 • Mar 06
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?분석 기사 • Dec 03
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk
Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) shares have retraced a considerable 66% in the last month, reversing...Seeking Alpha • Nov 03
Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges
Summary Prelude Therapeutics continues to explore the SMARCA2 anticancer approach, with no major hiccups disclosed to date. A strategic shift from their main pipeline contender raises concerns about data not yet disclosed, however. PRLD's funding situation is also in doubt, as they will find themselves needing to raise cash in the coming months. An upcoming ASH presentation could also shed some light on the next steps for two preclinical projects in myeloproliferative neoplasms. Read the full article on Seeking Alpha분석 기사 • Jun 16
Prelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Mar 17
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Feb 03
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Summary Prelude Therapeutics once produced positive clinical data from a now abandoned program. The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early preclinical data and look scientifically interesting. However, they are too early to merit an investment right now, although they bear watching. Read the full article on Seeking Alpha분석 기사 • Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...분석 기사 • May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Oct 18
Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Prelude Therapeutics (NASDAQ:PRLD), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent. A protein degrader targeted at SMARCA2 (BRM) mutations in cancer tissue, PRT3789, has demonstrated antitumor activity in preclinical models at well-tolerated doses, the company said. “Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic,” Dr. Peggy Scherle, Chief Scientific Officer of Prelude (PRLD), noted. The Phase 1 trial for PRT3789 is designed to enroll patients with advanced solid tumors harboring SMARCA4. The dosing is expected to start in Q1 2023. PRLD awaits multiple catalysts in its clinical programs this year.Seeking Alpha • Sep 09
Prelude downgraded at Morgan Stanley ahead of key update
Prelude Therapeutics (NASDAQ:PRLD) inched lower on Friday after Morgan Stanley downgraded the cancer-focused biotech to Equal Weight from Overweight as the company plans to disclose key steps forward for its PRMT5 program, including the solid tumor candidate PRT811 in H2 2022. The analysts see upside potential as PRLD remains on track to report early findings from its MCL1 inhibitor program and CDK9 inhibitor program during the second half of 2022. However, they see better opportunities elsewhere in the coverage noting uncertainty over the path forward for PRT811. Morgan Stanley lowers the probability of success for PRT811 in GBM, solid tumors, and myeloid malignancies to 20% from 25%, in line with the range it usually uses for Phase 1 assets, and trims the price target for PRLD to $11 from $19. Early this year, PRLD decided to drop the development of the PRT543 candidate in its PRMT5 program and focus its efforts on PRT811.분석 기사 • Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$78m |
| Dec 31 2025 | US$1m | US$615k | -US$99m |
| Sep 30 2025 | n/a | n/a | -US$112m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$128m |
| Dec 31 2024 | US$2m | US$594k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$130m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$573k | -US$122m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$117m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$558k | -US$115m |
| Sep 30 2022 | n/a | n/a | -US$120m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$7m | US$544k | -US$112m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$12m | US$417k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$315k | -US$28m |
보상 대 시장: Kris의 총 보수(USD1.35M)는 US 시장에서 비슷한 규모 기업의 평균(USD2.64M)보다 낮습니다.
보상과 수익: Kris의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Kris Vaddi (59 yo)
10.3yrs
재임 기간
US$1,348,000
보수
Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 10.3yrs | US$1.35m | 3.1% $ 13.3m | |
| CFO, Chief Legal Officer & Corporate Secretary | 3.3yrs | US$847.40k | 0.027% $ 117.0k | |
| Chief Scientific Officer | 8.1yrs | US$819.73k | 0.18% $ 792.9k | |
| Senior VP and Head of Strategic Planning & Operations | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Technical Operations | 5.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Investor Relations | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 4.9yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Chemistry Officer | 7.1yrs | US$2.63m | 0.48% $ 2.1m | |
| Senior Vice President of Translation Medicine | 4.4yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Clinical Development | 3.6yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Clinical Pharmacology | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | 2.1yrs | 데이터 없음 | 0.099% $ 427.0k |
4.4yrs
평균 재임 기간
56yo
평균 나이
경험이 풍부한 관리: PRLD의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.4 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder | 10.3yrs | US$1.35m | 3.1% $ 13.3m | |
| Independent Chairman of the Board | 9.8yrs | US$102.53k | 0.50% $ 2.1m | |
| Independent Director | 4.8yrs | US$78.53k | 0% $ 0 | |
| Independent Director | 9.9yrs | US$86.03k | 0% $ 0 | |
| Independent Directors | less than a year | US$77.56k | 데이터 없음 | |
| Independent Director | 6yrs | US$194.53k | 0% $ 0 | |
| Independent Directors | less than a year | US$81.57k | 데이터 없음 |
6.0yrs
평균 재임 기간
59yo
평균 나이
경험이 풍부한 이사회: PRLD의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 20:30 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Prelude Therapeutics Incorporated는 6명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |